Vanguard Portfolio Management
IBRX icon

Vanguard Portfolio Management’s ImmunityBio IBRX Stock Holding History

Vanguard Portfolio Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156M Buy
17,863,911
+1,541,067
+9% +$11.7M 0.01% 1333
2026
Q1 		$125M Buy
+16,322,844
New +$112M 0.01% 1357

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Portfolio Management's IBRX Position: Q2 2026 in Review

Vanguard Portfolio Management increased its ImmunityBio (IBRX) stake by 9.4% in Q2 2026, buying an estimated $11.7M and bringing the position to 17,863,911 shares worth $156M. The position accounts for 0.01% of the portfolio, ranked #1333.

Vanguard Portfolio Management first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 402 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Vanguard Portfolio Management held 17,863,911 shares of ImmunityBio worth $156M as of Q2 2026.
  • Vanguard Portfolio Management bought 1,541,067 ImmunityBio shares in Q2 2026, an estimated $11.7M.
  • ImmunityBio made up 0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1333 holding.
  • Vanguard Portfolio Management first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 402 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.